The estimated Net Worth of Daniel J. Becker is at least $170 Million dollars as of 19 November 2020. Daniel Becker owns over 197,716 units of Pandion Therapeutics stock worth over $169,814,374 and over the last 5 years Daniel sold PAND stock worth over $0.
Sign up
Daniel Becker PAND stock SEC Form 4 insiders trading
Daniel has made over 5 trades of the Pandion Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Daniel bought 197,716 units of PAND stock worth $2,989,466 on 19 November 2020.
The largest trade Daniel's ever made was buying 723,222 units of Pandion Therapeutics stock on 17 July 2020 worth over $13,017,996. On average, Daniel trades about 176,504 units every 44 days since 2019. As of 19 November 2020 Daniel still owns at least 2,827,883 units of Pandion Therapeutics stock.
You can see the complete history of Daniel Becker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Daniel Becker's mailing address?
Daniel's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.
Insiders trading at Pandion Therapeutics
Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol..., and Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.
What does Pandion Therapeutics's logo look like?
Complete history of Daniel Becker stock trades at Principia Biopharma and Pandion Therapeutics
Pandion Therapeutics executives and stock owners
Pandion Therapeutics executives and other stock owners filed with the SEC include:
-
Capital Management, L.P.Kol...,
-
Nancy Stagliano,
Director -
Vikas Goyal,
See Remarks -
Joanne L. Viney,
See Remarks -
Partners Gp Viii, L.L.C.Pol...,
-
Rizzuto Carlo,
Director -
Jill Carroll,
Director -
Katina Dorton,
Director -
Donald Frail,
Director -
Christopher Fuglesang,
Director -
Gregg Beloff,
See Remarks -
Alan L Crane,
Director -
Mitchell Mutz,
Director -
Eric D Larson,
Vice President, Finance -
Daniel J. Becker,
Director -
Rahul Kakkar,
Chief Executive Officer -
Plc Gsk,
Director -
John Sundy,
Chief Medical Officer -
Edward D. Freedman,
Chief Operating Officer